Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Operating Expenses: 2020-2025

Historic Operating Expenses for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $26.3 million.

  • Silence Therapeutics' Operating Expenses fell 5.45% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year decrease of 64.87%. This contributed to the annual value of -$18.9 million for FY2024, which is 69.70% down from last year.
  • Latest data reveals that Silence Therapeutics reported Operating Expenses of $26.3 million as of Q3 2025, which was up 679.03% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Operating Expenses ranged from a high of $143.1 million in Q4 2023 and a low of -$15.5 billion during Q1 2021.
  • Over the past 3 years, Silence Therapeutics' median Operating Expenses value was $121,000 (recorded in 2025), while the average stood at $14.4 million.
  • As far as peak fluctuations go, Silence Therapeutics' Operating Expenses tumbled by 99.58% in 2021, and later soared by 258.32% in 2024.
  • Quarterly analysis of 5 years shows Silence Therapeutics' Operating Expenses stood at $119.9 million in 2021, then dropped by 3.54% to $115.6 million in 2022, then increased by 23.76% to $143.1 million in 2023, then plummeted by 80.70% to $27.6 million in 2024, then dropped by 5.45% to $26.3 million in 2025.
  • Its Operating Expenses stands at $26.3 million for Q3 2025, versus $3.4 million for Q2 2025 and $121,000 for Q1 2025.